Home General Biotechnology Drug Patent Expirations in December 2013

Drug Patent Expirations in December 2013

Drug Patent Expirations for December 2013

TradenameApplicantGeneric NamePatent NumberPatent Expiration
EMADINEAlconemedastine difumarate5,441,958Dec 8, 2013
ENTEREGCubist Pharmsalvimopan5,434,171Dec 8, 2013
EDARBYCLORArbor Pharms Llcazilsartan kamedoxomil; chlorthalidone5,583,141Dec 10, 2013
SOLAGEAqua Pharmsmequinol; tretinoin5,194,247Dec 10, 2013
EDARBIArbor Pharms Llcazilsartan kamedoxomil5,583,141Dec 10, 2013
CYMBALTALillyduloxetine hydrochloride5,023,269*PEDDec 11, 2013
ABREVAGlaxosmithklinedocosanol5,534,554Dec 13, 2013
LUPRON DEPOT-PEDAbbvie Endocrine Incleuprolide acetate6,036,976Dec 13, 2013
FROVAEndo Pharmsfrovatriptan succinate5,962,501Dec 16, 2013
MYLOTARGWyeth Pharms Incgemtuzumab ozogamicin5,585,089Dec 17, 2013
AGENERASEGlaxosmithklineamprenavir5,585,397Dec 17, 2013
DEFINITYLantheus Medclperflutren5,585,112Dec 17, 2013
AEROSPAN HFAActon Pharmsflunisolide5,980,867Dec 20, 2013
DDAVPSanofi Aventis Usdesmopressin acetate5,674,850Dec 23, 2013
DDAVP (NEEDS NO REFRIGERATION)Sanofi Aventis Usdesmopressin acetate5,674,850Dec 23, 2013
VIOXXMerckrofecoxib6,239,173*PEDDec 24, 2013
VIOXXMerckrofecoxib5,474,995*PEDDec 24, 2013
ANTHELIOS SXLoreal Usaavobenzone; ecamsule; octocrylene5,587,150Dec 24, 2013
EFFEXOR XRWyeth Pharms Incvenlafaxine hydrochloride5,916,923*PEDDec 28, 2013
EFFEXOR XRWyeth Pharms Incvenlafaxine hydrochloride6,444,708*PEDDec 28, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.